Page 14 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $10.45
52wk Low $4.17 Anavex Life Sciences Corp. AVXL $4.45
630 5th Avenue
New York, NY 10111

(USD - in millions) www.anavex.com
Market Cap 365.4
Enterprise 221.6
Basic Shares Out. 82.11 COMPANY OVERVIEW
Float 79.52
Institutional Holdings 31.68% Detailed Analysis:Channelchek.com
Short Interest 22.12
Avg. 90-Day Volume 1.25 Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded
biopharmaceutical company dedicated to the development of novel
therapeutics for the treatment of neurodegenerative and
neurodevelopmental disorders, including Alzheimer's disease,
EPS Data Parkinson's disease, Rett syndrome, schizophrenia and other central
nervous system (CNS) diseases, pain, and various types of cancer.
2021 2022 2023 Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has
CQ1 (0.12) (0.14) (0.17) successfully completed a Phase 2a and a Phase 2b/3 clinical trial for
CQ2 (0.14) (0.16) (0.14) Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's
disease dementia, and both a Phase 2 and a Phase 3 study in adult
CQ3 (0.15) (0.18) (0.12) patients and one Phase 2/3 in pediatric patients with Rett syndrome.
CQ4 (0.14) (0.17) (0.11)
CY (0.55) (0.65) (0.54) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.65
ROE (ttm) -31.88
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 30-Sep
630 5th AvenuNew York NY 10111

Key Executives
CEO: Missling, Christopher
CFO: Boenisch, Sandra
COO: Toutain, Stephan
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures